Mazdutide Phase 3 trial (NCT05606913)
Efficacy and Safety of IBI362 Versus Dulaglutide as add-on to Metformin and/or SGLT2 Inhibitor or TZD in Subjects With Type 2 Diabetes (DREAMS-2)
Registry record checked
At a glance
- Phase
- Phase 3
- Status
- Completed
- Enrolment
- 731
- actual
- Start
- 6 Jan 2023 (actual)
- Primary completion
- 26 Jan 2024 (actual)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Design
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| IBI362 6.0mg | Experimental | Drug: IBI362 | ①2mg, SC, once a week\* 4weeks; ②4mg, SC, once a week\* 4weeks;③6mg, SC, once a week\* 20weeks. |
| dulaglutide | Experimental | Drug: dulaglutide | 1.5mg, SC, once a week\* 28weeks |
| IBI362 4.0mg | Experimental | Drug: IBI362 | 2mg, SC, once a week\* 4weeks; ②4mg, SC, once a week\* 24weeks. |
Endpoints
Primary endpoint
| Measure | Time frame |
|---|---|
| HbA1c change from baseline at week 28 | Baseline, 28 weeks |
Endpoints
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| percent change from baseline in body weigh | Baseline, 28 weeks |
| Proportion of subjects with HbA1c <7.0% and weight loss ≥5% from baseline | Baseline, 28 weeks |
| Change from baseline in HbA1c (superiority) | Baseline, 28 weeks |
| Proportion of subjects with HbA1c <7.0% | Baseline, 28 weeks |
| Safety,Incidence and severity of adverse events and correlation with study drug; | Baseline to 32weeks |
| Time to peak plasma concentration (Tmax) | Baseline to 28weeks |
| Time to peak plasma concentration (Cmax) | Baseline to 28weeks |
| area under curve (AUC) | Baseline to 28weeks |
| volume distribution (V) | Baseline to 28weeks |
| half-life (half-life, T1/2 | Baseline to 28weeks |
| clearance rate (clearance, CL) | Baseline to 28weeks |
| To assess changes in PD parameters fasting insulin at different time points before and after administration. | Baseline to 28weeks |
Eligibility
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- Not stated
Results
Results
No results posted on ClinicalTrials.gov as of 2 Oct 2026.
Sources
- 1Efficacy and Safety of IBI362 Versus Dulaglutide as add-on to Metformin and/or SGLT2 Inhibitor or TZD in Subjects With Type 2 Diabetes (DREAMS-2)ClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
Found an error? Report a correction.